Darzalex Faspro

News

Two boxes and vials of Talvey, different doses

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

News

J&J says 2026 sales could top $100 billion

J&J says its sales should top $100 billion this year, as it pushes its oncology business towards a target of $50 billion by the end of the decade.

News

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

News

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?

News

Mixed outcomes for pharma in big week for FDA adcomms

There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.

News

J&J bids to add smouldering myeloma to Darzalex label

Johnson & Johnson has reported positive phase 3 data with Darzalex in smouldering multiple myeloma (SMM), just before filing applications for the drug in this indication in Europe and t

Data could move J&J's Talvey earlier in myeloma therapy

J&J says 2026 sales could top $100 billion

J&J claims FDA's latest national priority voucher

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Mixed outcomes for pharma in big week for FDA adcomms

J&J bids to add smouldering myeloma to Darzalex label

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Discover a new era of healthcare panel engagement: Grounded ...

Darzalex Faspro

Editor's Picks